THE European Medicines Agency
has recommended the suspension
of marketing authorisations for oral
ketoconazole, sold as Nizoral.
The EMA’s Committee on
Medicinal Products for Human Use
has concluded that the risk of liver
injury is greater than the benefits in
treating fungal infections.
Doctors are being told to stop
prescribing the oral medication, but
topical formulations continue to be
approved because they have very
low systemic absorptionThe above article was sent to subscribers in Pharmacy Daily's issue from 29 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jul 13
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.